Search
Meet the team behind the CIRCA DIEM study.
The CIRCA DIEM Trial Steering Committee provides independent oversight and strategic guidance for the study.
A sub-study is an ‘add-on’ study that helps to answer specific questions within a larger research project. If you decide to participate in the CIRCA DIEM study, you or your child may be invited to take part in one of the CIRCA DIEM sub-studies.
The CIRCA DIEM study aims to establish if cycling environmental light and noise levels for premature infants during their initial hospital stay leads to earlier development of circadian (daily) rhythms and better outcomes for the preterm babies, including improved brain development.
Surfactant replacement therapy by nebulization to spontaneously breathing patients has been regarded as the Holy Grail since surfactant deficiency was first identified as the cause for neonatal respiratory distress syndrome. It avoids neonatal endotracheal intubation, a procedure that is often difficult and occasionally harmful.
High-frequency oscillatory ventilation (HFOV) is an established mode of respiratory support in the neonatal intensive care unit. Large clinical trial data is based on first intention use in preterm infants with acute respiratory distress syndrome. Clinical practice has evolved from this narrow population. HFOV is most often reserved for term and preterm infants with severe, and often complex, respiratory failure not responding to conventional modalities of respiratory support.
To examine follow-up outcomes at corrected postnatal age (cPNA) 2 years of preterm infants previously enrolled in an RCT and treated with IN-REC-SUR-E or IN-SUR-E in 35 tertiary neonatal intensive care units.
Instability of peripheral oxyhemoglobin saturation (SpO2) in preterm infants is correlated with late disability and is poorly understood. We hypothesised that a reduced ventilation to perfusion ratio (VA/Q) is the key predisposing factor for SpO2 instability.
Despite advances in immunotherapy, metastatic melanoma remains a considerable therapeutic challenge due to the complexity of the tumor microenvironment. Intratumoral type I interferon (IFN-I) has long been associated with improved clinical outcomes. However, several IFN-I subtypes can also paradoxically promote tumor growth in some contexts.
The Chronobiology team works to understand the factors that contribute to poor lung and heart function in newborn infants and find ways to prevent heart and lung disease.